In this episode, we explore the DanGer Shock study, which investigated the efficacy of the microaxial flow pump Impella CP in reducing mortality and improving clinical outcomes in patients with STEMI-related cardiogenic shock. We delve into the study's design, statistical findings, clinical recommendations, and the future of mechanical circulatory support in cardiology, highlighting both the benefits and risks of this advanced technology as published in the NEJM.
📚 Source: Study Title: Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock Trial) Publication Date: April 2024 Journal: NEJM DOI:10.1056/NEJMoa2312572
Podden och tillhörande omslagsbild på den här sidan tillhör
Mohammed Al-Qadami. Innehållet i podden är skapat av Mohammed Al-Qadami och inte av,
eller tillsammans med, Poddtoppen.